Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO6860 Phase I Safety, PK, and PD Study in Healthy Subjects
NCT02337543Phase 1Completed
- Sponsor
- Neomed Institute
- Start
- Jan 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NEO6860 in osteoarthritis (OA) (3 arms), sponsored by Neomed Institute. Primary endpoint: Safety and tolerability of NEO6860 at 10 days. Started Jan 2015; status: completed.
02
Drugs
NEO6860
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02337543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337543.